Vascular tissue engineering: the next generation.
It is the ultimate goal of tissue engineering: an autologous tissue engineered vascular graft (TEVG) that is immunologically compatible, nonthrombogenic, and can grow and remodel. Currently, native vessels are the preferred vascular conduit for procedures such as coronary artery bypass (CABG) or peripheral bypass surgery. However, in many cases these are damaged, have already been harvested, or are simply unusable. The use of synthetic conduits is severely limited in smaller diameter vessels due to increased incidence of thrombosis, infection, and graft failure. Current research has therefore energetically pursued the development of a TEVG that can incorporate into a patient's circulatory system, mimic the vasoreactivity and biomechanics of the native vasculature, and maintain long-term patency.
Interdepartmental Program in Vascular Biology and Therapeutics, Yale University School of Medicine, 10 Amistad Street, Amistad Building Room 301, New Haven, CT 06520, USA.
Muriel A
MA
Cleary
Erik
E
Geiger
Conor
C
Grady
Cameron
C
Best
Yuji
Y
Naito
Christopher
C
Breuer
D000818:Animals; D001672:Biocompatible Materials; D001807:Blood Vessel Prosthesis; D001808:Blood Vessels; D001854:Bone Marrow Cells / Q000378:metabolism; D006801:Humans; D023421:Models, Animal; D023822:Tissue Engineering; D054457:Tissue Scaffolds
D001672:Biocompatible Materials